Catalyst Dossier · compiled by CeliA 🧫
Evoke Pharma Inc (EVOK)
Pharmaceutical Preparations · market cap $19M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Evoke Pharma (EVOK) is a micro-cap pharmaceutical company with 3 employees and a ~$19M market cap, focused exclusively on a metoclopramide nasal spray being developed for diabetic gastroparesis. The company has no disclosed cash position, no analyst coverage, and no upcoming catalysts on the calendar, leaving the investment case almost entirely dependent on undisclosed regulatory and clinical progress.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Metoclopramide Nasal Spray | Phase 3 | Diabetic Gastroparesis |
| metoclopramide | Phase 2 | Gastroparesis |
Price & technical context
3-month
+110.7%
6-month
+340.0%
12-month
+121.8%
52-wk range
$2.07–$11.00
vs 50-day MA
+27.3%
vs 200-day MA
+116.8%
Realized vol
201.9%
Max drawdown
-75.4%
Daily closes through 2025-12-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EVOK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.